P.B.M.W.M. Timmermans

Dow Chemical (Belgium) — Belgium

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index5.5kcitations123works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(60), Neuroscience and Neuropharmacology Research(25), Neuropeptides and Animal Physiology(18), Eicosanoids and Hypertension Pharmacology(16), Analytical Methods in Pharmaceuticals(14)

Publications123 total

Ethylated Phosphorylcholine as a New Marker for Alcohol Consumption: A Proof of Concept
Drug Testing and Analysis·2025
Ethylated phosphorylcholine – a new marker for ethanol consumption: A proof of concept
Annales de Toxicologie Analytique·2025
Pharmacological properties of angiotensin II receptor antagonists.
PubMed·1999· 79 cited
Historical development of losartan (DuP 753) and angiotensin II receptor subtypes.
PubMed·1996· 7 cited
Discovery of losartan, the first angiotensin II receptor antagonist.
PubMed·1995· 58 cited
EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
Journal of Pharmacology and Experimental Therapeutics·1993
Angiotensin II receptors and angiotensin II receptor antagonists.
Pharmacological Reviews·1993· 1.9k cited
AT2 Receptors Mediate the Release of Prostaglandins in Porcine Smooth Muscle Cells and Rat Astrocytes
American Journal of Hypertension·1992· 33 cited
Multiple angiotensin receptors: Selective ligands and functional correlates
The Japanese Journal of Pharmacology·1992· 1 citedOpen Access
Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
Journal of Pharmacology and Experimental Therapeutics·1991· 53 cited
Angiotensin II receptor antagonists. From discovery to antihypertensive drugs.
Hypertension·1991· 70 cited
Comparison of inhibitory potency by nonpeptide angiotensin II receptor antagonists PD123177 and DuP 753 on proximal nephron and renal transport.
Journal of Pharmacology and Experimental Therapeutics·1991· 55 cited
Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753.
Journal of Pharmacology and Experimental Therapeutics·1991· 45 cited
Effect of angiotensin II antagonism on canine renal sympathetic nerve function.
Hypertension·1991· 49 cited
Effects of DuP 753 on Renal Function of Normotensive and Spontaneously Hypertensive Rats
American Journal of Hypertension·1991· 41 cited
Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
Circulation·1991· 249 citedOpen Access
Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.
Hypertension·1990· 131 citedOpen Access
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
Journal of Pharmacology and Experimental Therapeutics·1990· 270 cited
Effect of a monoclonal antibody to angiotensin II on hemodynamic responses to noradrenergic stimulation in pithed rats.
Hypertension·1989· 20 citedOpen Access
Characterization of a Panel of Monoclonal Antibodies Against Human Tissue-Type Plasminogen Activator
Hybridoma·1988· 5 cited
page 1 of 7Next →

Frequent Co-authors

Pieter A. van Zwieten(12), Pancras C. Wong(9), Mjmc Thoolen(9), P. A. van Zwieten(8), David J. Carini(6), Ruth R. Wexler(6), A. de Jonge(6), Bob Wilffert(6), Andrew T. Chiu(5), J. C. A. van Meel(5), B. Wilffert(5), John V. Duncia(4), P. A. van Zwieten(4), Roger Smith(3), William A. Price(3), A.L. Johnson(3), P. A. VAN ZWIETEN(3), Pa Vanzwieten(3), Martin Thoolen(3), P. A. van Zwieten(3)